Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 7/20 | 0.34 |
| ▸ | GLB1 | P16278 | 1/20 | 0.34 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.33 |
| ▸ | GUSB | P08236 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11807350 | 1.00 | PSMD14 (0.34) | PSMD14MMP2RAD52GBA1GLB1 | |
| SCHEMBL322316 | 1.00 | PSMD14 (0.34) | PSMD14MMP2RAD52GBA1GLB1 | |
| SCHEMBL8031986 | 1.00 | PSMD14 (0.34) | PSMD14MMP2RAD52GBA1GLB1 | |
| SCHEMBL8038131 | 1.00 | PSMD14 (0.34) | PSMD14MMP2RAD52GBA1GLB1 | |
| SCHEMBL2007679 | 1.00 | PSMD14 (0.34) | PSMD14MMP2RAD52GBA1GLB1 | |
| SCHEMBL9955184 | 1.00 | PSMD14 (0.34) | PSMD14MMP2RAD52GBA1GLB1 | |
| SCHEMBL8034064 | 1.00 | PSMD14 (0.34) | PSMD14MMP2RAD52GBA1GLB1 | |
| SCHEMBL5986996 | 1.00 | PSMD14 (0.34) | PSMD14MMP2RAD52GBA1GLB1 | |
| SCHEMBL8035780 | 0.94 | PSMD14 (0.40) | PSMD14MMP2RAD52GBA1GLB1 | |
| SCHEMBL8032041 | 0.94 | PSMD14 (0.40) | PSMD14MMP2RAD52GBA1GLB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2654665-A2 | METHOD FOR DEVELOPING A LIQUID COMPOSITION TO BE APPLIED TO THE SKIN AS A FOAM AND A COMPOSITION THAT CAN BE APPLIED TOPICALLY | MIKA Pharma Gesellschaft für die Entwicklung und Vermarktung pharmazeutischer Produkte mbH (DE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012083906-A2 | METHOD FOR DEVELOPING A LIQUID COMPOSITION TO BE APPLIED TO THE SKIN AS A FOAM AND A COMPOSITION THAT CAN BE APPLIED TOPICALLY | MIKA PHARMA GESELLSCHAFT FÜR DIE ENTWICKLUNG UND VERMARKTUNG PHARMAZEUTISCHER PRODUKTE MBH (DE) | 2012-06-28 | — | — | WO | disclosed |